Navigation Links
Warner Chilcott Reports Operating Results for the Quarter Ended March 31, 2009 and Updates 2009 Full Year Guidance
Date:5/11/2009

proximate impact of the above items. The Company also believes that considering the effect of these items allows management and investors to better compare the Company's financial performance from period-to-period, and to better compare the Company's financial performance with that of its competitors. The presentation of this additional information is not meant to be considered in isolation of, or as a substitute for, results prepared in accordance with US GAAP.

Adjusted EBITDA

To supplement its condensed consolidated financial statements presented in accordance with US GAAP, the Company is providing a summary to show the computation of adjusted earnings before interest, taxes, depreciation and amortization ("EBITDA") taking into account certain charges that were taken during the quarters ended March 31, 2009 and 2008. The computation of adjusted EBITDA is based on the definition of EBITDA contained in the indenture governing the Company's Senior Subordinated Notes due 2015.



                              WARNER CHILCOTT LIMITED
                   CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
               (In thousands of U.S. dollars, except per share amounts)
                                    (Unaudited)

                                                         Quarter Ended
                                                     Mar-31-09  Mar-31-08
     REVENUE:
             Product net sales                        $239,024   $223,700
             Other revenue                               6,965      5,783
                 Total revenue                         245,989    229,483

     COSTS & EXPENSES:
             Cost of sales (excludes amortization)      48,750     47,770
             Selling, general and administrative        46,766     55,227
             Research and development                   23,872     12,180
             Amortization of intangible assets          56,9
'/>"/>
SOURCE Warner Chilcott Limited
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine news :

1. Warner Chilcott Proposes Redomestication From Bermuda to Ireland
2. Warner Chilcott to Present at the Bank of America and Merrill Lynch 2009 Health Care Conference
3. Warner Chilcott Files New Lawsuit for Infringement of DORYX(R) Patent
4. HBO, Warner Bros. Employee Initiatives and the Alzheimers Association, California Southland Chapter Present a Free, Public, Advance Screening of THE ALZHEIMERS PROJECT: Caregivers
5. Warner Chilcott Announces Earnings Release Date and Conference Call For First Quarter 2009 Financial Results
6. Warner Chilcott Files New Lawsuit for Infringement of DORYX(R) Patent
7. Warner Chilcott Announces Receipt of FDA Response to Citizen Petition
8. Warner Chilcott Announces Receipt of Paragraph IV Certification Notice
9. Virginia Faith Leaders Call on Senators Webb & Warner to Support Legislation to Protect Kids from Tobacco
10. Virginia Faith Leaders Call on Sens. Webb & Warner to Support Legislation to Protect Kids From Tobacco
11. Warner Chilcott Reports Operating Results for the Quarter and Year Ended December 31, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... McCullers, MD, was recently invited to submit a ... Reviews Microbiology , one of the world,s foremost ... disease specialist, and chair of the Department of ... Center, analyzed the epidemiology and microbiology of co-infections ... well as more recent 2009 novel H1N1 pandemic. ...
(Date:4/17/2014)... Doctors who treat patients with a severe ... face an agonizing treatment decision. , The drug ... help relieve shortness of breath. But some patients ... cause potentially fatal complications following transplantation. , "It,s ... medical director of Loyola University Medical Center,s LAM ...
(Date:4/17/2014)... 17, 2014-- Colic affects about one in five infants ... pediatric visits during the first several months after birth. ... was showing promise; however, the April 1, 2014 issue ... Valerie) reported on a study, "Probiotics and Infant Colic," ... reuteri for infant colic did not reduce ...
(Date:4/17/2014)... EcoHealth Alliance, a nonprofit organization that focuses on ... review today examining the current state of knowledge of ... for improved global surveillance strategies to combat the emergence ... Ebola in West Africa that has claimed the lives ... Liberia. According to the World Health Organization (WHO), ...
(Date:4/17/2014)... international research team led by Cesar A. Arias, M.D., ... at Houston (UTHealth) has identified a new superbug that ... report appeared in the April 17 issue of ... new superbug is part of a class of highly-resistant ... MRSA, which is a major cause of hospital and ...
Breaking Medicine News(10 mins):Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 2Health News:Re-emergence of Ebola focuses need for global surveillance strategies 3Health News:New MRSA superbug emerges in Brazil 2
... the World; First Centers to Open ... France and China, Kenneth P. Moritsugu, M.D., Former Acting Surgeon General, Appointed to ... Lead Global ... today announced the establishment of the Johnson &,Johnson Diabetes Institute (JJDI) to transform diabetes ...
... IT Services Leader Will Provide Systems Operations, ... Military Health System Computing Environment, ARLINGTON, ... leading global,provider of information management and business ... awarded the Military Health System,Executive Information and ...
... MedPredict Market Research,a global provider of pharmaceutical ... report providing critical strategic insight,for pharma and biotech ... anxiety and,depression therapies. In this report, entitled ... physician experts from North America and Europe,discuss the ...
... and Oncology is pleased to announce that Stefanie LaRue of ... Circle Award winner. Ms. LaRue will be presented with her ... 2007, at 8:00 a.m. at the Los Angeles Convention Center ... 28 through November 1 in Los Angeles., The Survivor Circle ...
... existing regimen may help, researchers say , TUESDAY, Oct. ... as an added therapy, the epilepsy drug lamotrigine is ... , The 239 participants, aged 13 and older, were ... They were already taking one or two medications, but ...
... For the seventh,consecutive year West Coast Bank will partner ... the Heart of Doernbecher Auction, which,has raised over $2.5 ... tie event will be held at Portland Art Museum, ... Bank,s Executive Vice President of Commercial Banking Xandra,McKeown serves ...
Cached Medicine News:Health News:Johnson & Johnson Launches Global Diabetes Institute to Provide State-of-The- Art Education, Training to Health Professionals 2Health News:Johnson & Johnson Launches Global Diabetes Institute to Provide State-of-The- Art Education, Training to Health Professionals 3Health News:Johnson & Johnson Launches Global Diabetes Institute to Provide State-of-The- Art Education, Training to Health Professionals 4Health News:Vangent, Inc. Awarded Contract to Support Military Health System's Executive Information and Decision Support Program 2Health News:New Report Provides Insight Into Developments in the Market for Anxiety and Depression Therapies 2Health News:LA breast cancer activist honored with Survivor Circle Award 2Health News:LA breast cancer activist honored with Survivor Circle Award 3Health News:Lamotrigine May Reduce Epilepsy Seizures 2Health News:West Coast Bank Will Sponsor the Heart of Doernbecher Auction at the Portland Art Museum, October 20, 2007 2
(Date:1/15/2014)... Jan. 15, 2014 MultiCell Technologies, Inc. (OTC Bulletin ... provisional patent application concerning composition of matter, biological targets, ... tumor cell death.  This patent application ... stranded RNA molecules (VSRNAs) which interfere with the basic ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium Research ... market intelligence, the United States ... device markets will expand moderately through 2022, with ... In particular, increasing interest in drug-eluting beads (DEBs) ...
(Date:1/15/2014)... LAVAL, Quebec , Jan. 15, 2014  Valeant Pharmaceuticals ... VRX) announced that the applicable waiting period under the ... to the previously announced tender offer by its indirect ... the outstanding shares of common stock of Solta Medical, ...
Breaking Medicine Technology:MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3
... Presented Along With Updated Phase 1 Colorectal Cancer ... Data at ... CHICAGO, June 1 /PRNewswire-FirstCall/,-- Poniard Pharmaceuticals, Inc. (Nasdaq: PARD ... results,from its ongoing randomized Phase 2 clinical trial in patients ...
... Greater Than 50% Response Rate and 100% Disease Control Rate Observed ... Patients with Medullary Thyroid Cancer, ... encouraging new data from an ongoing phase 1 clinical trial of,XL184, ... with advanced malignancies. The maximum tolerated dose (MTD) for,XL184 has been ...
Cached Medicine Technology:Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 2Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 3Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 4Poniard Announces Positive Preliminary Efficacy and Safety Data From Ongoing Phase 2 Trial of Picoplatin in First-Line Treatment of Colorectal Cancer 5Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 2Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 3Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 4Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 5Exelixis Reports Encouraging Phase 1 Data for XL184 at ASCO 6
The UniCel DxI 800 with its exceptional throughput, proven chemiluminescent technology, assay protocols like Access, Access 2, Synchron LXi 725 and load "on-the-fly" capability simplifies and automat...
... The Access immunoassay system ... access benchtop analyzer that ... assays, with panels that ... thyroid, infectious disease, blood ...
...
...
Medicine Products: